Last updated: September 24, 2026
Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution is an established topical antibiotic combination used for bacterial eye infections. The commercial product, commonly associated with Polytrim, contains polymyxin B sulfate at 10,000 units/mL and trimethoprim sulfate at 1 mg/mL. Its formulation is aqueous, multidose, preserved, and relatively simple. The primary commercial opportunities are preservative-free delivery, improved tolerability, unit-dose packaging, differentiated viscosity, broader antimicrobial positioning, and lower-cost generic supply.
The combination has limited expected value from conventional composition-of-matter patents because both active ingredients are old antibiotics. Value is more likely to come from formulation execution, manufacturing reliability, device compatibility, regulatory positioning, and supply economics.
What is the approved formulation of polymyxin B sulfate and trimethoprim sulfate?
The reference ophthalmic product is an aqueous solution containing:
| Component |
Function |
Typical labeled concentration |
| Polymyxin B sulfate |
Antibacterial active |
10,000 units/mL |
| Trimethoprim sulfate |
Antibacterial active |
1 mg/mL |
| Benzalkonium chloride |
Preservative |
0.04 mg/mL |
| Sodium chloride |
Tonicity adjustment |
Quantity sufficient |
| Hydrochloric acid or sodium hydroxide |
pH adjustment |
Quantity sufficient |
| Purified water |
Vehicle |
Quantity sufficient |
The FDA labeling describes the product as a sterile ophthalmic solution for topical administration. The commercial formulation uses benzalkonium chloride, or BAK, as a multidose preservative. BAK is effective against microbial contamination but can cause ocular-surface irritation, particularly with repeated administration or in patients with pre-existing dry eye, corneal disease, contact-lens intolerance, or chronic topical-drug exposure. (U.S. Food and Drug Administration [FDA], n.d.-a)
The formulation is not a suspension or ointment. That distinction matters commercially because a clear solution supports low-cost filling, conventional ophthalmic dropper packaging, and relatively simple patient administration.
What excipient strategy supports a competitive product?
A competitive excipient strategy should preserve antimicrobial potency, solution clarity, sterility, drop consistency, and chemical stability while reducing preservative burden.
Preservative strategy
The largest formulation opportunity is a preservative-free presentation. Potential formats include:
- Blow-fill-seal unit-dose vials
- Preservative-free multidose bottles using a validated sterile barrier system
- Metered-dose ophthalmic containers
- Small-volume single-use ampoules
A preservative-free version could target patients who require repeated treatment, have ocular-surface sensitivity, or receive multiple topical ophthalmic products. The tradeoff is higher packaging cost, more complex filling operations, increased material consumption, and potentially lower prescription-channel margins.
A reduced-BAK formulation is another option, although it may create limited differentiation unless the product demonstrates meaningful tolerability benefits or supports a specific clinical segment. Replacing BAK with alternative preservatives such as polyquaternium-1, stabilized oxychloro complex, or oxidative preservative systems would require compatibility, antimicrobial effectiveness, ocular tolerability, and regulatory support.
Tonicity and buffering
Sodium chloride is used to manage osmolality. A buffer system may improve pH control, but excessive buffering can increase ocular discomfort. The formulation should target acceptable physiologic tolerability without creating precipitation or degradation risks.
Trimethoprim sulfate is water-soluble, but the final pH and ionic environment can affect stability and comfort. Polymyxin B is a mixture of related cyclic polypeptide components. Its activity and assay require control of biological potency rather than relying only on conventional small-molecule chromatographic testing.
Viscosity modifiers
A modest viscosity increase could extend ocular residence time and reduce drainage. Candidate excipients may include hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, carbomer, or polyethylene glycol systems.
Viscosity modification creates several technical risks:
- Blurred vision after administration
- Slower drop formation and inconsistent dosing
- Increased preservative challenge
- Compatibility problems with container closure systems
- Greater difficulty in sterilizing or filtering the formulation
- Potential alteration of polymyxin B potency or trimethoprim stability
A low-viscosity formulation is more suitable for a broad generic market. A moderately viscous product may support a premium positioning if tolerability and dosing convenience are demonstrated.
Surfactants and solubilizers
Surfactants should be used conservatively. They can improve wetting and container-drainage performance but may increase ocular irritation or interact with polymyxin B. The commercial benefit is usually lower than the formulation and packaging risk unless the product has a specific solubility or delivery problem.
What formulation patents protect polymyxin B and trimethoprim ophthalmic products?
The active ingredients have long histories of medical use, and the commercial product is an established ophthalmic combination. Broad patent protection for polymyxin B sulfate or trimethoprim sulfate is therefore unlikely to block a new generic product.
The relevant intellectual-property categories are narrower:
| IP category |
Commercial relevance |
| Combination formulation patents |
Potentially relevant if they claim a specific ratio, pH range, preservative system, or stability profile |
| Preservative-free delivery patents |
Relevant to multidose sterile containers and unit-dose systems |
| Container-closure patents |
Relevant to metered-dose or preservative-free packaging |
| Manufacturing patents |
Relevant to polymyxin B potency, purification, sterilization, and filling |
| Method-of-use patents |
Likely limited for an old topical antibacterial combination |
| Trade secrets |
Potentially important for stability, filling, and release testing |
A product-specific freedom-to-operate review must distinguish patents covering the active pharmaceutical ingredients from patents covering the formulation and delivery system. A generic solution using the same actives and similar inactive ingredients may have low patent risk but still face regulatory requirements for pharmaceutical equivalence, microbial quality, stability, and container performance.
What is the Orange Book status and exclusivity outlook?
The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Established ophthalmic antibiotic combinations generally have limited remaining exclusivity value compared with recently approved small-molecule products. The key commercial questions are whether the reference product has active listed patents, whether any listing remains enforceable, and whether the product is eligible for an abbreviated new drug application, or ANDA, pathway. (FDA, n.d.-b)
For an old polymyxin B and trimethoprim ophthalmic solution, the principal barriers are usually technical and regulatory rather than a long remaining exclusivity period:
- Demonstrating pharmaceutical equivalence
- Matching strength and dosage form
- Establishing sterility and preservative effectiveness
- Showing container-closure integrity
- Demonstrating stability throughout the proposed shelf life
- Addressing polymyxin B potency and mixture composition
- Establishing acceptable in vitro or clinical performance where required
A Paragraph IV challenge could be relevant only if an active patent is listed against the reference product. For a mature product, an ANDA applicant may instead pursue a Paragraph III certification, a section viii statement for a carved-out indication, or a certification that no listed patent blocks approval. The commercial value of a Paragraph IV strategy depends on the actual Orange Book listing and patent expiration dates at filing.
When does polymyxin B and trimethoprim lose market exclusivity?
The active ingredients lost basic exclusivity many years ago. Market access is therefore driven by product-specific approval status, manufacturing capacity, and distribution rather than new-molecule exclusivity.
A simplified commercial timeline is:
| Period |
Commercial implication |
| Historical period |
Original combination developed and approved as an ophthalmic antibacterial |
| Generic era |
ANDA-based competition becomes possible |
| Current market |
Competition is primarily based on price, availability, bottle size, preservative profile, and contracting |
| Future differentiated products |
New value may come from preservative-free delivery, packaging, or improved tolerability |
The absence of basic exclusivity does not eliminate commercial opportunity. Ophthalmic products can experience shortages, manufacturer exits, contract disruptions, and quality-related supply constraints. A reliable supplier can obtain market share even without a differentiated patent estate.
What manufacturing and IP barriers affect commercial entry?
Polymyxin B creates greater manufacturing complexity than trimethoprim. It is a mixture of closely related polypeptide components, and the product must meet potency and quality specifications while maintaining batch-to-batch consistency.
Key manufacturing barriers include:
-
Active ingredient consistency. Polymyxin B sulfate requires control of potency, component distribution, impurities, and microbiological quality.
-
Sterile processing. The finished ophthalmic solution must be sterile and filled into a validated container-closure system.
-
Preservative effectiveness. Multidose products must pass antimicrobial effectiveness testing under the applicable pharmacopeial framework.
-
Container compatibility. Adsorption, extractables, leachables, drop-size variability, and closure integrity can affect product performance.
-
Stability. The manufacturer must establish chemical, physical, microbiological, and functional stability.
-
Analytical capability. Release testing must support both trimethoprim assay and polymyxin B biological potency.
These barriers favor manufacturers that already operate sterile ophthalmic lines. A company with oral solid-dose capacity but no sterile ophthalmic platform would face a materially higher entry burden.
What commercial opportunities exist for new excipient systems?
Preservative-free unit-dose product
This is the clearest differentiation strategy. It can target:
- Pediatric and geriatric patients
- Dry-eye patients
- Postoperative patients receiving multiple eye drops
- Contact-lens users after appropriate clinical instructions
- Hospitals seeking reduced preservative exposure
The disadvantages are packaging cost, lower manufacturing throughput per dose, and more complicated logistics.
Preservative-free multidose bottle
A validated multidose system could combine the convenience of a bottle with the tolerability profile of a preservative-free product. The main IP risk would shift from drug formulation to device and dispensing technology. The product would require strong container-performance data and a clear regulatory strategy.
Improved comfort formulation
A formulation with lower preservative exposure, optimized osmolality, reduced buffering, and a controlled pH could compete on patient experience. This opportunity is commercially stronger if supported by comparative tolerability data rather than an excipient substitution alone.
Viscosity-enhanced formulation
A mildly viscous solution could support less frequent administration or longer ocular residence. The product would need to avoid clinically meaningful blurring and maintain predictable drop delivery.
Hospital and institutional supply
Hospitals may value dependable supply, unit-dose packaging, tamper evidence, and simplified inventory management. Institutional contracts can support a product with modest unit-price premiums if the manufacturer reduces waste or supply interruptions.
How does this product compare with competing ophthalmic antibiotics?
| Product type |
Main advantage |
Main limitation |
| Polymyxin B/trimethoprim solution |
Established combination and broad practical use |
BAK exposure and mature generic competition |
| Fluoroquinolone ophthalmic solution |
Broad antibacterial activity and strong generic availability |
Resistance, stewardship concerns, and intense price competition |
| Aminoglycoside-containing products |
Low-cost antibacterial option |
Ocular-surface tolerability concerns |
| Ophthalmic antibiotic ointments |
Longer ocular residence |
Blurred vision and less convenient administration |
| Preservative-free antibiotic products |
Better fit for sensitive ocular surfaces |
Higher packaging and manufacturing cost |
The combination remains commercially relevant where prescribers prefer a non-fluoroquinolone option or where formulary policy favors older, lower-cost antibiotics. Its competitive weakness is the lack of strong exclusivity and the presence of multiple low-cost alternatives.
Which companies are positioned to challenge or supply the market?
The market is accessible to generic ophthalmic manufacturers, specialty sterile-fill companies, and branded manufacturers with established eye-care portfolios. Potential competitors are determined less by molecule ownership than by:
- FDA-approved sterile ophthalmic manufacturing
- Existing ophthalmic sales infrastructure
- Ability to source qualified polymyxin B sulfate
- Capacity for small-volume sterile filling
- Access to hospital and retail distribution
- Ability to maintain supply during shortages
A new entrant with a preservative-free container system could compete against conventional generic bottles without relying on a new active ingredient.
What revenue exposure and launch scenarios are realistic?
The product is best viewed as a mature, price-sensitive ophthalmic antibiotic. Revenue depends on prescription volume, channel mix, reimbursement, generic count, and supply reliability. A conventional generic launch would likely face rapid price compression. A differentiated launch may support better economics but would require development spending and potentially clinical or human-factors evidence.
| Launch model |
Revenue profile |
Main risk |
| Low-cost conventional generic |
Volume-driven |
Rapid price erosion |
| Preservative-reduced product |
Moderate premium potential |
Limited differentiation without clinical support |
| Preservative-free unit-dose |
Higher unit price |
Packaging and manufacturing cost |
| Preservative-free multidose |
Strong differentiation |
Device and regulatory complexity |
| Hospital-focused product |
Contracted, predictable demand |
Tender pricing and supply obligations |
Key Takeaways
- Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution is a mature antibacterial product with limited expected basic patent protection.
- The reference formulation uses an aqueous vehicle, sodium chloride, pH adjustment, and benzalkonium chloride preservative.
- The strongest commercial opportunity is a preservative-free unit-dose or validated preservative-free multidose product.
- A viscosity-enhanced formulation may create differentiation but carries comfort, clarity, dosing, and stability risks.
- Manufacturing capability for sterile ophthalmic products and polymyxin B potency control is a more important barrier than active-ingredient IP.
- Conventional generic entry is likely to be price competitive; differentiated packaging and ocular-surface tolerability can support premium positioning.
- Orange Book, patent-listing, and Paragraph IV conclusions must be tied to the current FDA reference-product record and any active listed patents.
FAQs
Is polymyxin B and trimethoprim ophthalmic solution a generic drug?
Yes. The active ingredients are old antibacterial agents, and the combination is available in generic-style products. Product-specific approval, manufacturing, and quality requirements still apply.
Can benzalkonium chloride be removed from the formulation?
Yes, but removing BAK requires a different preservation and packaging strategy. A unit-dose package avoids repeated-container contamination risk, while a preservative-free multidose bottle requires specialized dispensing technology and validation.
Does polymyxin B create unusual analytical testing requirements?
Yes. Polymyxin B is a mixture of related polypeptide components, so potency, identity, impurity, and component-profile testing require more specialized methods than trimethoprim alone.
Is a new excipient enough to obtain meaningful patent protection?
Usually not. Patent strength would depend on a specific, non-obvious formulation or delivery system that provides demonstrated stability, tolerability, dosing, or preservation benefits.
What is the most attractive commercial format?
A preservative-free product in a low-waste unit-dose or validated multidose container is the most defensible opportunity. A conventional preserved bottle is easier to manufacture but is likely to compete mainly on price and supply reliability.
References
-
U.S. Food and Drug Administration. (n.d.-a). Polymyxin B sulfate and trimethoprim sulfate ophthalmic solution prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.
-
United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products: Quality tests. United States Pharmacopeial Convention.
